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ABSTRACT 
Subcallosal Brodmann’s Area 25 (Cg25) Deep Brain Stimulation (DBS) is a new 
promising therapy for treatment resistant major depressive disorder (TR-MDD). While 
different DBS stimulating parameters may have an impact on the efficacy and safety 
of the therapy, there is no data to support a protocol for optimal stimulation 
parameters for depression. Here we present a prospective multi-center double-blind 
randomized crossed-over 13-month study that evaluated the effects of High (130 Hz) 
vs Low (20 Hz) frequency Cg25 stimulation for nine patients with TR-MDD. Four out 
of nine patients achieved response criteria (≥40% reduction of symptom score) 
compared to mean baseline values at the end of the study. The mean percent 
change of MADRS score showed a similar improvement in the high and low 
frequency stimulation groups after 6 months of stimulation (-15.4±21.1 and -
14.7±21.1 respectively). The mean effect at the end of the second period (6 months 
after cross-over) was higher than the first period (first 6 months of stimulation) in all 
patients (-23.4±19.9 (n=6 periods) and -13.0±22 (n=9 periods) respectively). At the 
end of the second period, the mean percent change of the MADRS scores improved 
more in the high than low frequency groups (-31.3±19.3 (n=4 patients) and -7.7±10.9 
(n=2 patients) respectively). Given the small numbers, detailed statistical analysis is 
challenging. Nonetheless the results of this study suggest that long term high 
frequency stimulation might confer the best results. Larger scale, randomized double 
blind trials are needed in order to evaluate the most effective stimulation parameters. 
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INTRODUCTION 
Deep Brain Stimulation (DBS) is a relatively new therapy whose potential has been 
explored in the recent years for treatment resistant major depressive disorder (TR-
MDD) [Delaloye and Holtzheimer, 2014; Coenenet al, 2015; Bewernicket al, 2017]. 
The first reported brain target for stimulation is the subcallosal white matter, 
Brodmann’s Area 25 (Cg25) [Mayberg et al, 2005]. Cg25 stimulation has been 
reported to lead to beneficial responses in approximately 50% of patients suffering 
from severe TR-MDD; Lozano et al (2008) and Holtzheimer et al (2012) reported one 
year response rate of 62% and 36% respectively. The failure of the therapy in the 
remaining patients, however, indicates that this brain target or the mode of 
stimulation might not have a therapeutic relevance for all patients. While most 
research groups have examined the individual symptom profiles and the effects of 
stimulation in other areas of the brain or sub-locations within the Cg25 area, different 
modes of stimulation have hardly been studied [Holtzheimer et al, 2012; Schlaepfer 
et al, 2008, 2014; Hoyer et al, 2012; Riva-Posse et al, 2014; Bergfeld et al, 2016; 
Bewernick et al, 2010]. Only one group reported that short term (one week) different 
frequencies (0, 5, 20, 50, 130 and 185 Hz) of Cg25 stimulation in four patients did not 
yield clinical change [Ramasubbu et al, 2013]. 
The initial DBS stimulating parameters (such as high frequency) used in clinical 
depression studies are in essence the same as those used for Parkinson’s disease 
[Lozano et al, 2008; Bewernick et al, 2010]. Few publications have described the 
impact of parameter settings on the efficacy of DBS in movement disorders such as 
Parkinson’s disease and dystonia, recommending frequency optimization to balance 
efficacy and side-effects [Moreau et al, 2013; Eusebio et al, 2008; Xie et al, 2015; 
Vallabhajosula et al, 2015]. Preclinical studies explored the anti-depressant like 
effects of different stimulation settings at the parallel target of the Subcallosal 
Cingulate gyrus in both naïve rats and in a rat model of depression [Hamani et al, 
2010; Lim et al, 2015]. It was therefore considered possible that in patients with TR-
MDD, different DBS stimulating parameters may have an impact on the efficacy and 
safety of the therapy.  
There is no evidence-based data to support a protocol for optimization of stimulation 
in TR-MDD and adjustment of optimal stimulation parameters is guided by the 
clinician’s knowledge and experience. Using a lower frequency may provide better 
efficacy as well as a health-economic advantage. Lowering the frequency from 130 to 
20 Hz could extend the neurostimulator battery life by a factor of 5, avoiding the need 
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for future multiple battery changes with all the associated surgical risks and costs. 
The goal of this double blind cross-over study was to investigate the impact of 
different DBS parameter settings (high (130 Hz) vs low (20 Hz) frequency) on the 
efficacy and safety of Cg25 DBS as an adjunctive treatment for patients with TR-
MDD.   
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METHODS 
Study Design 
This clinical study was designed as a prospective, multi-center, double-blind, 
randomized, 13-month study to evaluate the effects of high (130 Hz) vs. low (20 Hz) 
frequency Cg25 DBS as an adjunctive treatment for single or recurrent episode TR-
MDD. The study design is illustrated in Figure 1. After having 2 baseline evaluations 
by 2 separate psychiatrists, eligible patients were implanted with the Libra® DBS 
System. All patients underwent a 4 week surgical recovery period during which the 
system was not activated. One month after implantation, patients were randomized 
(1:1) to 2 different treatment groups (high vs low frequency) and their system was 
activated. Once activated, patients returned to the clinic for efficacy and safety 
evaluations every month. Both the evaluating psychiatrists as well as the patients 
were blinded to which stimulation group they were randomized. Each patient’s device 
was programmed by one clinician and the information regarding the device was not 
given to the evaluating psychiatrists. The evaluating psychiatrists were the same 
throughout the patient study treatment and follow-up visits, in order to reduce 
variability in the evaluators’ scoring.  
After 6 months of active stimulation (i.e. at the 7-month post-implant visit) patients 
were evaluated based on their MADRS (Montgomery and Asberg Depression Rating 
Scale) score as either being a responder or non-responder: responders (≥40% 
reduction of the MADRS score compared to mean baseline values) continued with 
their treatment in the same frequency group for another 6 months; non responders 
crossed over to the other frequency group, still in a double-blind way, for the 
following 6 months. A threshold for response of 40% reduction in MADRS had been 
used in previous DBS studies [Lozano et al, 2008] and adopted for this cross-over 
design to enable patients with a prominent clinical improvement after 6 months of 
active stimulation to continue with their probable effective treatment. 
The primary objective was to evaluate the effect of two different frequency settings of 
Cg25 DBS on mood, measured as the percentage of change from baseline value in 
the MADRS score after six months of active stimulation.  
The secondary objectives were to evaluate the safety and efficacy of the same two 
frequency settings for DBS on mood after 3, 6, 9 and 12 months of active stimulation 
as measured by MADRS, Hamilton Rating Scale for Depression [HRSD-17], Quick 
Inventory of Depressive Symptoms-Self Report [QIDS-SR]), quality of life (Quality of 
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Life and Satisfaction Questionnaire [Q-LES-Q]), functioning (Global Assessment of 
Functioning [GAF]), anxiety (Hamilton Anxiety Rating Scale [HAM-A]), Clinician and 
Patient Global Impression of Severity and Improvement (CGI; PGI) and cognitive 
function (CANTAB battery). Safety measures included the incidence of depression 
related and device related adverse events (i.e. hospitalization due to worsening 
depression, suicidal ideation, or behavior, medical treatment, and device related 
events) that occur over study duration. 
The clinical investigation plan, screening and subject selection procedures and 
description of the investigational device are detailed in the method section of the 
supplementary data.  
 
DBS System Implantation 
The technique to insert bilateral DBS electrodes into white matter of Cg25 in detailed 
in the method section of the supplementary data. The target was planned as 
previously described [Mayberg et al, 2005; Lozano et al, 2008; Hamani et al, 2009]. 
An example of the specific target on a reconstruction of post-operative CT and pre-
operative MRI is illustrated in Figure 2. 
Stimulation Parameters  
The initial stimulated contact was the second most distal contact on the lead, unless 
post-operative lead placement showed a different contact to be more optimal. The 
scans were reviewed by an expert team and recommendations made for the order of 
contact stimulation on each side. The initial device settings at the beginning of 
stimulation and after crossover were monopolar stimulation with amplitude 4mA, 
pulse width 91µSec and frequency 130Hz for the high frequency group or 20Hz for 
the low frequency group.  
For both groups, parameters of stimulation were fixed during the study and only 
minor adjustments in amplitude made to optimize clinical effects (as measured by the 
MADRS) were allowed at monthly evaluations. If a patient did not response and did 
not improve according to the clinical evaluation and the MADRS (MADRS decrease 
<10% from previous evaluation), the amplitude was increased with 2mA up to 8mA 
(highest amplitude allowed). A change in contacts was made if there was either no 
response or worsening using higher (8.0mA) current. The new contact was the 
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second recommended contact and the settings were monopolar stimulation with 
current 4mA.  
Concomitant Medications 
All patients could maintain their anti-depressant medication regimen as well as any 
regularly scheduled psychotherapy. During the study (from the first baseline meeting 
to the end of the study) patients did not receive new medications (excluding sleep 
aids and other drugs to manage non-depression related conditions) nor increased 
current antidepressant medication doses. 
Statistical Methods 
Efficacy data are presented primarily on an intention-to-treat basis, meaning that all 
randomized patients were included in the analyses and data are presented as per the 
randomized treatment with last observation carried forward. Due to the small number 
of patients recruited to this study, statistical tests were not used and percent changes 
are simply compared to one another at face value.   
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RESULTS 
The data for a total of 9 patients from 3 sites who participated in this study have been 
analyzed (see demographic details in Table 1).  
As shown in Table 2, four out of nine patients achieved the response criterion at the 
end of the study (≥40% reduction of the MADRS score compared to mean baseline 
values). The mean percent change from baseline of MADRS score showed an 
improvement in both high and low frequency groups after 3 and 6 months of 
stimulation, indicating that the degree of severity of depressive symptoms had 
decreased. After cross-over the MADRS scores improved further in both groups, with 
better results in the high frequency group.  
Of the initial patients, only 6 out of 9 patients participated in the second phase of the 
study (6-12 months after stimulation was initiated) and only 5 out of 9 patients were 
crossed-over to the other frequency stimulation group. Two patients (no. 7 and no. 8) 
chose to withdraw after 6 months of active stimulation due to a lack of change in their 
clinical state. One patient (no. 3) that had a significant clinical improvement after 3 
months of active stimulation was unable to comply with study requirements and 
withdrew. Patient no. 9 experienced a satisfactory functional improvement after 6 
months and asked not to be crossed-over; she agreed to continue the blinded follow-
up protocol. The study team accepted all these patients’ requests. 
The primary endpoint of the cross-over study was the percentage of change in the 
MADRS score after six months of active stimulation. In this analysis the results of 6 
months of stimulation (the first period of the study) were compared to the mean 
baseline score while the results of 6 months of stimulation after cross-over (the 
second period of the study) were compared to the results at the time of cross-over 
(i.e., 7 months after surgery). As shown in Figure 3a, in the analysis of the cross-over 
study, the mean percent change of MADRS score showed an improvement in the all 
patients group as well as in each of the high and low frequency stimulation groups, 
after 6 months of active stimulation (-15.1 ±20.2; -15.4 ±21.1 and -14.7 ±21.1 
respectively).  
This study could not demonstrate a significant difference in MADRS score change in 
high vs low frequency stimulation (Figure 3a). Hence, the primary endpoint of the 
study was not achieved. The HRSD showed a mild improvement with the low 
frequency stimulation while the QIDS, CGI and PGI showed a mild improvement with 
the high frequency stimulation (Figure 3b). The mean GAF score showed an overall 
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improvement in functioning of the patients after 6 and 12 months of stimulation, with 
better results in the high frequency group. The mean Q-LES-Q score showed 
improvement in the patient’s overall quality of life after 12 months of stimulation but 
only for the high frequency group. According to the clinicians and patients' global 
impression scale the severity of illness score improved from "markedly ill" to "mildly 
ill" or "moderately ill" after 12 months of stimulation for the high frequency group but 
no improvement was demonstrated for the low frequency group. The same scale 
showed that the patients were 'minimally improved' for the low frequency group and 
'much improved' for the high frequency group after 12 months of stimulation. 
Comparison of the effect of stimulation in the first period of the study (prior to cross-
over) and the second period of the study (after cross-over) yielded notable findings, 
as illustrated in Figure 4a. The mean effect at the end of the first period was less than 
the mean effect at the second period in all patients (-13.0 ±22 and -23.4 ±19.9 
respectively). The mean effect of the first period was higher than mean effect of the 
second period in the low frequency group (-18.3 ±25.5 and -7.7 ±10.9 respectively). 
On the contrary, the mean effect of the first period was lower than mean effect of the 
second period in the high frequency group (-8.7 ±20.6 and -31.3 ±19.3 respectively). 
The mean percent change with high frequency stimulation after the cross-over was 
close to response criteria. Figure 4b shows that all the other tests (HRSD, QIDS, CGI 
and PGI) demonstrated similar results to the MADRS score.   
For further evaluation, we divided the patients into a high then low frequency 
stimulation group versus a low then high frequency stimulation group, using intention 
to treat analysis. As illustrated in Figure 5, low followed by high frequency stimulation 
was more effective than high followed by low frequency stimulation (percent change 
of MADRS at the end of the study was -36.2 ±23.5 and -6.4 ±25.2 respectively). The 
mean percent change with low then high stimulation was close to the response 
criterion. All the other scales (HRSD, QIDS, CGI and PGI) demonstrated similar 
results to the MADRS scale. 
Table 3 demonstrates the results of the cognitive tests (the CANTAB battery). 
Analysis of the cognitive tests reveals improvement after 12 months of stimulation in 
most tested cognitive aspects (one-touch stocking of Cambridge; spatial span; rapid 
visual information processing; affective go-no go) while partial or no improvement 
was demonstrated in two tests (delayed matching to sample; choice reaction time). 
Of note, similar to the improvement in the MADRS scale, the improvement in 
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cognitive tests in the “low then high” frequency stimulation group was greater than 
that in the “high then low” frequency stimulation group. 
All patients were evaluated twice at 2 and at 4 weeks after the implantation, before 
randomization and at the start of stimulation. Only a small mean change of MADRS 
from baseline was found 2 weeks and 4 weeks post-operation (-9.8 ±21.6 and -0.9 
±11.3, respectively). The patients who were responders at the end of the study had a 
higher improvement of the MADRS score at both 2 and 4 weeks post-operation (-15 
±13.9 and -8.7 ±12.1 respectively) compared to non-responders (-5.6 ±27.2 and 5.2 
±6.2 respectively).  
Forty adverse events were reported and only one of these events was reported as a 
serious adverse event (SAE). 28 adverse events were reported as being possibly or 
definitely related to the device/procedure, of which 13 and 15 events were reported 
before the stimulation was activated and during active stimulation respectively, with 
no difference between high and low frequency stimulation groups. A detailed list of 
adverse events can be found in the result section of the supplementary data.      
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DISCUSSION  
This study was designed as a prospective, multi-center, double-blind, randomized, 
and controlled study lasting 13 months from implantation, with 2 different treatment 
groups: subcallosal cingulate DBS with high frequency versus low frequency. This is 
the first study evaluating the most effective stimulation parameters for DBS in a TR-
MDD population. Given the small numbers, detailed statistical analysis remains 
challenging. Nonetheless given that in most DBS for depression studies the number 
of patients is small (see meta-analysis by Nangunoori et al, 2013), the results of the 
study here present a significant contribution to the literature, being the largest 
published double-blind study of Cg25 DBS for depression.  
As measured by a range of validated scales, depression, anxiety, daily functioning, 
symptom severity, severity of illness, quality of life and cognitive aspects all improved 
after DBS. Of note, the patients who were responders at the end of the study had a 
higher improvement of the MADRS score at both 2 and 4 weeks post-operation. 
Reduction of symptoms at this period is usually considered as an insertion effect, 
secondary to the mild edema as the electrode reaches the target [Mestre et al, 2016]. 
Our preliminary results suggest that the insertion effect might be a predictor for future 
clinical improvement. 
Only one of the nine patients was responder after 6 months of stimulation, in contrast 
to previous open studies that reported 40-60% response rate after 6 months [Lozano 
et al, 2008; Holtzheimer et al, 2012]. Open label methodology has many 
disadvantages and a significant placebo bias effect. Although the patients/providers 
were blinded to stimulation parameters, they were aware that a procedure had been 
performed so a placebo effect in this study cannot be excluded. However, we believe 
that the lower response rate mainly reflects the double-blind methodology of our 
study.  
Three out of six patients responded well to prolonged treatment at 12 months of 
stimulation. Increased response rate over time is in line with previous depression 
DBS studies [Lozano et al, 2008; Holtzheimer et al, 2012; Bergfeldet al 2016; 
Bewernick et al 2010; Kennedy et al 2011; Crowell et al, 2015]. This is also not 
unusual with other conditions treated with DBS, such as dystonia, where prolonged 
stimulation appears necessary to produce optimal clinical benefit. Long-term DBS 
probably causes neuroplasticity and CNS remodeling effects that are necessary for 
the treatment response [Timmermann et al, 2004]. Notwithstanding this, with 
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depression caution is warranted as even severe disease could be self-limiting and its 
natural history might yield similar results.   
We did not demonstrate a significant difference in MADRS score percent change in 
high vs low frequency stimulation, but it was interesting that high frequency 
stimulation yielded better results than low frequency stimulation after 6 months of 
stimulation. The short term (first 6 months) effect of stimulation was better in the low 
frequency group while the long term (second 6 months) effect of stimulation was 
superior in the high frequency group. The lack of significance might be due to the 
small sample size. It should be mentioned that these differences could also be 
explained by differences in group composition (for example, the group that began 
with low-frequency stimulation may have been more responsive to the treatment). A 
longer duration of stimulation might be required to observe a change in symptomatic 
response, regardless of frequency. For both groups, figure 5 shows linear changes in 
MADRS over time that are consistent across both stimulation periods. However, our 
results may imply that long term brain plasticity is divergently influenced by 
stimulation frequency. 
Differential effects of high and low frequency stimulation are also reported in other 
diseases. Most of the optimization protocols for subthalamic stimulation in 
Parkinson’s disease recommend high frequency stimulation although some studies 
reported that low frequency subthalamic nucleus stimulation reduced side effects 
such as aspiration, axial instability, freezing of gait and word fluency [Xie et al, 2015; 
Vallabhajosula et al, 2015; Timmermann et al, 2004; Wojtecki et al, 2006; Hamani et 
al, 2010].   
Recent animal studies support the high frequency stimulation paradigm for 
depression. Hamani et al. (2010) studied the impact of different DBS stimulation 
settings such as amplitude and frequency (130 vs 20 Hz) in the ventromedial 
prefrontal cortex (vmPFC), the parallel target of the Subcallosal Cingulate gyrus that 
is used in clinical studies, in naïve rats. They found that the anti-depressant like 
effects of DBS varied as a function of stimulation settings and high frequency was 
more effective than low frequency stimulation. Lim et al (2015), found that high 
frequency (100 Hz) but not low frequency (10 Hz) stimulation of the vmPFC improved 
various depression-related behavior in both naïve rats and in a rat model of 
depression. The findings in these animal studies are therefore in keeping with what 
we found in our study here. 
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Over and above the direct findings of this study, there were important lessons to be 
learned from its scientific and organizational design which should help better plan 
future DBS studies for psychiatric indications [Fins et al, 2017]. 
Double blind DBS studies. DBS for depression is an experimental treatment. Until 
now most of the studies that evaluated the effectiveness of DBS for depression were 
not randomized controlled studies [Lozano et al, 2008; Holtzheimer et al, 2012; 
Bewernick et al, 2010; Nangunoori et al, 2013; Kennedy et al, 2011; Crowell et al, 
2015; Loxano et al, 2012; Puigdemont et al, 2012]. Randomized controlled trials 
(RCTs) are considered to be the gold-standard to determine efficacy and safety. It is 
well known that in clinical studies for depression the placebo rate is high. The 
placebo effect and its moderators have been examined extensively in adult 
populations with major depressive disorder [Jakovljević, 2014]. It is important to 
mention that the placebo effect is related to the severity of depression. In the most 
severely depressed patients, the response to placebo and to active drugs is small 
and the drug–placebo differences are relatively modest [Licht et al, 2013]. The 
placebo response in depression is large in both pharmacological and non-
pharmacological interventions [Brunoni et al, 2009]. It is also clear that the operation 
and electrode implantation have a high placebo rate and in the past, sham surgeries 
have demonstrated dramatic placebo effects [Tavel, 2014]. Therefore, it is extremely 
important to test the efficacy of DBS for TR-MDD using a double-blind design. Most 
recently, two reported studies used a double-blind design for Cg25 stimulation but 
had a small number of patients and short stimulation duration: Ramasubbu et al 2013 
(4 patients; 3 months) and Puigdemont at al 2015 (5 patients; 6 months). A 
prospective, randomized trial of Cg25 stimulation for severe, medically refractory 
MDD (the BROADEN study) was discontinued after the results of a futility analysis 
predicted the probability of a successful study outcome to be low (no published data 
yet available). Another study used a double-blind design for Ventral Anterior Limb of 
the Internal Capsule stimulation (16 patients, 3 months) and found that during active 
DBS patients scored significantly lower on depression scales than during sham DBS 
[Bergfeld et al, 2016].   
Number of patients. This study aimed to recruit of 60 patients over 2 years. The 
recruitment was prematurely stopped after 9 patients. Future studies should consider 
the difficulties in recruiting large numbers of TR-MDD patients for DBS treatment. 
These difficulties could be due to the perception of DBS as an invasive procedure by 
physicians and the patients as well as strict inclusion/exclusion criteria. In most 
centers, this study was the first to treat depression with DBS procedure in the city or 
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state. As DBS becomes more popular in psychiatry we hope that more physicians 
and patients would positively consider participating in DBS studies. Another 
important barrier in recruiting a large sample of patients is the high cost of DBS 
studies. In DBS studies, on top of the regular expanses of recruitment, evaluation 
and follow-up, the budget includes operation, device and long term programming 
follow-up. In addition to difficulties with patient recruitment, we faced a high rate of 
patient attrition; 3 out of 9 patients (33%) were unavailable for assessment at the 12 
month follow-up. The attrition rate reported in long-term depression treatment studies 
is usually relatively high; 23% after 3-6 months of treatment and 47% after 12 months 
of treatment [Warden et al, 2009a; Warden et al, 2009b]. Other preliminary DBS 
studies for depression also reported a relative high patient attrition rate after 12 
months (20% by Kennedy et al, 2010; 26% by Malone et al, 2009).    
Multi-center DBS studies. This study aimed at recruitment from 8 centers. Actual 
recruitment was done only in 3 centers. DBS treatment requires a dedicated 
multidisciplinary team of psychiatrists, neurosurgeons, psychologists and 
neurologists. All expertise should be available in the same center to provide complete 
care. Split site working with patients receiving their psychiatric care in one center 
whilst undergoing neurosurgery at a different center is unlikely to encourage 
confidence and recruitment for this group of patients. Future studies should consider 
the ability and willingness of different centers to provide this expertise individually 
and then collaborate in a multi-center study.  
Quantitative rating scales and cognitive assessment. While only one patient was 
a responder after 6 months of stimulation according to the MADRS scores, all the 
other scores (HRSD-17, QIDS-SR, Q-LES-Q, GAF, HAM-A, CGI and PGI) showed 
that the rating of depression, anxiety, daily functioning, symptom severity, severity of 
illness and quality of life had improved after 6 months of stimulation. Five out of 
seven cognitive tests revealed improvement after 12 months of stimulation. Future 
studies should consider how rating scales should be selected and completed and 
should be designed with both the patients’ and clinicians’ time in mind to eliminate 
unnecessary work and ensure data is collected completely. Specific rating scales 
should be chosen to focus the data collection within a specific area to minimize the 
amount of data that is collected.  
In conclusion, our study suggests that Cg25 DBS is a promising therapy for 
treatment-resistant major depressive disorder. Based on our current data, long term 
high frequency stimulation is likely to confer the best results. Larger scale 
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randomized double blind trials are needed in order to evaluate the most effective 
stimulation parameters for Cg25 DBS. 
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FIGURE LEGENDS 
 
Figure 1: The Study Design: One Year Double-blind Cross-over Study of High 
vs Low Frequency Stimulation.   
One month after implantation, patients were randomized (1:1) to 2 different treatment 
groups (High (130 Hz) frequency (solid blue line) vs Low (20 Hz) frequency (solid red 
line)) and their system was activated. After 6 months of active stimulation patients 
were evaluated based on their MADRS Score as either being a responder or non-
responder: responders (≥40% reduction of the MADRS score compared to mean 
baseline values) continued with their treatment in the same frequency group for 
another 6 months (blue and red solid lines); non responders crossed over to the 
other frequency group, still in a double-blind way, for the following 6 months (blue 
and red dashed lines). 
 
Figure 2: The Anatomic Target of Stimulation: Reconstruction of Post-
operative CT and Pre-operative MRI. 
An example of the location of the second most distal electrode contact is 
demonstrated in sagittal (a) and coronal (b) reconstruction images of post-operative 
CT and pre-operative MRI. 
 
 
Figure 3: Mean Percent Change at 6 Months of Active Stimulation with High vs 
Low Frequency Stimulation 
A. The mean percent change of MADRS (Montgomery and Asberg Depression 
Rating Scale) score at 6 months of active stimulation showed an improvement in all 
the patients (green) as well as in each of the high (blue) and low (red) frequency 
stimulation groups, after 6 months of stimulation. This analysis included both first and 
second episodes of patients # 1,2,4,5 and 6 but only first episode of patients # 3,7,8 
and 9. 
B. The mean (±SD) percent change at 6 months of active stimulation of MADRS, 
Hamilton Rating Scale for Depression (HRSD), Quick Inventory of Depressive 
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Symptoms-Self Report (QIDS), Clinician and Patient Global Impression of Severity 
and Improvement (CGI, PGI). 
 
Figure 4: Mean Percent Change with High vs Low Frequency Stimulation 
Before and After Cross-Over 
A. The mean percent change in MADRS (Montgomery and Asberg Depression 
Rating Scale) score at the first period (prior to cross-over) in all patients (n=9, green), 
high frequency (n=5, blue) and low frequency (n=4, red), and at the second period 
(after cross-over) in all patients (n=6, green), high frequency (n=4, blue) and low 
frequency (n=2, red) 
B. The mean (±SD) percent change at the first period (prior to cross-over) and at the 
second period (after cross-over) in all patients (green), high frequency (blue) and low 
frequency (red), as measured by MADRS, Hamilton Rating Scale for Depression 
(HRSD), Quick Inventory of Depressive Symptoms-Self Report (QIDS), Clinician and 
Patient Global Impression of Severity and Improvement (CGI, PGI). 
 
 
Figure 5: Mean Percent Change with High then Low vs Low then High 
Frequency Stimulation  
A. The mean percent change in MADRS (Montgomery and Asberg Depression 
Rating Scale) score over time of all patients (green), low followed by high frequency 
stimulation (dark gray) and high followed by low frequency stimulation (light gray), 
with last observation carried forward. Patient no 9 did not cross over and was 
excluded from this analysis.  
B. The mean (±SD) percent change over time of all patients (green), low followed by 
high frequency stimulation (dark gray) and high followed by low frequency stimulation 
(light gray), as measured by MADRS, Hamilton Rating Scale for Depression (HRSD), 
Quick Inventory of Depressive Symptoms-Self Report (QIDS), Clinician and Patient 
Global Impression of Severity and Improvement (CGI, PGI). 
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Table 1: Demographics 
Demographics 
 
High Frequency 
Stimulation Group* 
Low Frequency 
Stimulation Group* 
Overall 
 n=5 n=4 n=9 
Male n (%) 3 (60) 1 (25) 4 (44) 
Female n (%) 2 (40) 3 (75) 5 (66) 
Age, years (mean) 43 51 46 
Weight, kg (mean) 78 94 85 
Mean Baseline MADRS 
Score (mean ± SD) 34.7 ± 2.8 32.1 ± 2.6 33.5 ± 2.9 
 
*Based on group assignment at the Initial Programming Visit (Week 4) 
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Table 2: Individual and Mean MADRS Scores Over Time 
Individual and Mean MADRS Scores Over Time (months from start of active stimulation) 
Individual MADRS scores (% reduction of the MADRS score compared to baseline values) 
Mean MADRS scores (% mean reduction of the MADRS score compared to baseline ± SD) 
  Baseline 3 months 6 months 9 months  12 months  
High Frequency Stimulation Group* 
Patient no 2 34 35 (2.94) 38 (11.76) 29 (-14.71) 38 (11.76) 
Patient no 5 ** 39 29 (-25.64) 26 (-33.33) 27 (-30.77) 22 (-43.59) 
Patient no 7 # 35.5 37 (4.23) 36 (1.41)     
Patient no 8 # 31.5 37 (17.46) 33 (4.76)     
Patient no 9 ** 33.5 21 (-37.31) 24 (-28.36) 13 (-61.19) 13 (-61.19)  
Mean MADRS  
(% mean reduction 
compared to 
baseline ± SD)  
34.7 
31.8  
(-7.7 ±22.8) 
31.4  
(-8.8 ±20.6) 
28 
(-22.7 ±11.4)^ 
30 
(-15.9 ±39.1)^ 
Low Frequency Stimulation Group*  
Patient no 1 34.5 35 (1.45) 31 (-10.14) 34 (-1.45) 26 (-24.64) 
Patient no 3 ** ## 33 15 (-54.54)        
Patient no 4 ** 32.5 22 (-32.31) 28 (-13.85) 17 (-47.69) 14 (-56.92)  
Patient no 6 28.5 31 (8.77) 30 (5.26) 11 (-61.40) 26 (-8.77) 
Mean MADRS  
(% mean reduction 
compared to 
baseline ± SD)  
32.1 
25.7  
(-19.2 ±29.6) 
29.7 
(-18.3 ±25.5) 
20.7 
(-42.9 ±28.4) 
22 
(-37.9 ±25.4) 
 
All Patients  
Mean MADRS  
(% mean reduction 
compared to 
baseline ± SD)  
33.6 
29.1  
(-12.8 ±25.02) 
30.75 
(-7.8 ±16.5) 
21.83 
(-36.2 ±24.8) 
23.1 
(-30.6 ±28.6) 
Blue – Scores under high frequency stimulation, Red – Scores under low frequency 
stimulation, Bold – Scores that reached the response criteria (≥40% reduction of the MADRS 
score compared to mean baseline values). 
* Based on group assignment at the Initial Programming Visit (Week 4) 
** Patient achieved response criteria at the end of the study, i.e. ≥40% reduction of the 
MADRS score compared to mean baseline values.  
# Patient chose to withdraw.  
## Patient was unable to comply with study requirements and withdrew. 
^ Patient no 9 did not cross over and was excluded from this calculation. 
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Table 3: Results of Cognitive Tests  
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Cognitive Test Description & Results Unit Sense Ran
 
One-Touch Stockings of Cambridge (OTS) 
 
Problems solved on first choice  
The number of assessment problems on which the first box choice made was correct. 
- +ve 0-15 
  All Patients ** High then Low ** Low then High **  
Baseline 10 10.25 9.6 
After 12 months  10.6 10.5 11 
Delta change  0.6 0.25 1.4 
Median latency to correct 
The median latency, measured from the appearance of the stocking balls until the correct 
box choice was made, for assessment problems. 
ms -ve 0-∞ 
  All Patients ** High then Low ** Low then High **  
Baseline 29456 23529 35026 
After 12 months  18820 21199 14063 
Delta change -9636 -2330 -20963 
 
Spatial Span (SSP) 
 
SSP Span length (Forwards) 
The longest sequence successfully recalled by the subject. 
- +ve 
 
0-9 
 
  All Patients ** High then Low ** Low then High **  
Baseline 5.71 6.25 5 
After 12 months  5.85 5.75 6 
Delta change 0.14 -0.5 1 
 
Rapid Visual Information Processing (RVP) 
 
A Prime 
A’ (A prime) is the signal detection measure of sensitivity to the target, regardless of 
response tendency. In essence, this metric is a measure of how good the subject is at 
detecting target sequences. 
- +ve 
 
0-1 
 
 
  All Patients ** High then Low ** Low then High **  
Baseline 0.88 0.91 0.85 
After 12 months  0.89 0.91 0.86 
Delta change  0.01 0.00 0.01 
Median response latency 
The median response latency during assessment sequence blocks where the subject 
responded correctly. 
- -ve 
 
0-∞ 
 
  All Patients ** High then Low ** Low then High **  
Baseline 510.62 527.75 493.50 
After 12 months  477.36 469.37 488.00 
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Delta change -33.28 -58.37 -5.50 
 
Delayed Matching to sample (DMS) 
 
Percent correct                 
The percentage of assessment trials during which the subject selected the correct box on 
their first box choice. 
% +ve 
 
0-
100 
  All Patients ** High then Low ** Low then High **  
Baseline 82.5 87.5 77.5 
After 12 months  79.3 82.5 75.0 
Delta change -3.2 -5.0 -2.5 
Median correct latency 
The Median latency from the available choices being displayed to the subject choosing the 
correct choice on assessment trials where the subject’s first choice is correct. 
ms -ve 0-∞ 
 
  All Patients ** High then Low ** Low then High **  
Baseline 4389.4 4465.5 4313.2 
After 12 months  4381.4 4685.6 3975.8 
Delta change -7.9 220.1 -337.4 
Probability of error given error 
This measure reports the probability of an error occurring when the previous trial was 
responded to incorrectly. 
- -ve 
 
 
0-1 
  All Patients ** High then Low ** Low then High **  
Baseline 0.194 0 0.292 
After 12 months  0.269 0.276 0.262 
Delta change 0.074 0.276 -0.029 
 
Choice Reaction Time (CRT) 
 
Median latency 
The median latency of response (from stimulus appearance to button press) on assessed 
trials that were responded to correctly. 
ms -ve 0-∞ 
 
  All Patients ** High then Low ** Low then High **  
Baseline 361.9 360.6 363.2 
After 12 months  399.0 417.8 373.8 
Delta change 37.1 57.2 10.6 
 
Affective Go/No Go (AGN) 
 
Median affective response bias 
 
The Median time taken to respond correctly to each 
target word stimulus in the positive blocks minus the 
Median time taken to respond correctly to each target 
word stimulus in the negative blocks 
ms cx 0-∞ 
 
  All Patients*** High then Low*** Low then High***  
Baseline 76.1 137 55.8 
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* The sense of each measure is indicated by +ve (higher is better) or –ve (lower is better). Cx 
indicates complex score types where such correspondences cannot be stated.  
** All patients (n=8); High then low frequency (n=4); Low then high frequency (n=4) 
*** All patients (n=4); High then low frequency (n=1); Low then high frequency (n=3) 
 
 
 
After 12 months  37.7 125.5 -6.25 
Delta change -38.4 -11.5 -62.1 
Median correct latency (positive) The median time taken to respond correctly to each 
target word stimulus in the blocks with positive 
targets 
ms -ve 0-∞ 
 
  All Patients*** High then Low*** Low then High***  
Baseline 584.2 551 595.3 
After 12 months  520.8 530 516.2 
Delta change -63.4 -21 -79.1 
Median correct latency (negative) The median time taken to respond correctly to each 
target word stimulus in the blocks with negative 
targets 
ms -ve 0-∞ 
 
  All Patients*** High then Low*** Low then High***  
Baseline 540.5 484 559.3 
After 12 months  494.6 457.4 513.2 
Delta change -45.8 -26.5 -46.1 
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HIGHLIGHTS 
 
High (130 Hz) vs low (20 Hz) frequency Cg25 deep brain stimulation for depression 
Effect at 6 months after cross-over was higher than first 6 months of stimulation 
MADRS scores improved more in high than low frequency groups 
Long-term high frequency stimulation might confer the best results 
Larger scale trials are needed to evaluate the most effective stimulation parameters 
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